Cronos Group's stock traded lower on Tuesday, after the company reported its latest results.
The cannabis company reported revenue of C$5.6 million ($4.2 million) for the fourth quarter, up from $1.6 million a year ago. Its gross profit before fair value adjustments came in at C$2.5 million for the quarter.
For the full year, Cronos had a loss of -11 cents per share, compared to a profit of 1 cent a year earlier. Its full-year revenue of $15.7 million was higher than the previous year’s $4.1 million.
Mike Gorenstein, CEO of Cronos Group highlighted the company’s expanding presence in domestic and international markets, and its launch of iconic brands for the Canadian adult-use market. He also emphasized on the firm's research and development initiatives as well as its global partnerships. "We are proud of all we have accomplished in 2018 and in the fourth quarter. Over the past year, Cronos Group has diligently focused on our strategic objectives, which culminated in our transformative partnership with Altria Group Inc.," said Gorenstein.
Cronos shares declined more than -1% Tuesday.
The Aroon Indicator for CRON entered a downward trend on May 23, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 334 similar instances where the Aroon Indicator formed such a pattern. In of the 334 cases the stock moved lower. This puts the odds of a downward move at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where CRON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
CRON moved below its 50-day moving average on May 24, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on May 23, 2023. You may want to consider a long position or call options on CRON as a result. In of 112 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CRON just turned positive on May 19, 2023. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.597) is normal, around the industry mean (41.822). P/E Ratio (0.000) is within average values for comparable stocks, (52.961). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.710). CRON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (7.698) is also within normal values, averaging (55.800).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows